Regen BioPharma, Inc. develops biopharmaceutical therapies centered on autologous cell therapies, RNA- and DNA-based immunotherapy, and small molecules in immuno-oncology. Company news is anchored by HemaXellerate, an FDA-cleared IND stem cell-derived therapy designed to stimulate bone marrow activity and restore hematopoietic function in aplastic anemia.
Recurring updates cover HemaXellerate clinical-development planning, orphan-drug application activity with the FDA, and evaluation of broader uses for chemotherapy-induced bone marrow suppression. News also includes third-party research coverage and capital-market communications for the company’s OTC-traded common and preferred securities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.